2023
5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice
Jefferson S, Gregg I, Dibbs M, Liao C, Wu H, Davoudian P, Woodburn S, Wehrle P, Sprouse J, Sherwood A, Kaye A, Pittenger C, Kwan A. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology 2023, 48: 1257-1266. PMID: 37015972, PMCID: PMC10354037, DOI: 10.1038/s41386-023-01572-w.Peer-Reviewed Original ResearchConceptsMouse medial frontal cortexEarly phase clinical studiesDendritic spine densityHead-twitch responseDose-dependent increaseStructural neural plasticityMedial frontal cortexSpine densityClinical studiesFrontal cortexLong-term effectsDendritic spinesMental illnessNeural plasticitySpine formationPatient accessSubjective effectsNeural consequencesPotential therapeuticsSerotonergic psychedelicsAnxiety symptomsNeural mechanismsUltrasonic vocalizationsElevated ratesMice
2020
Chapter Four Clinical overview of NMDA-R antagonists and clinical practice
Davoudian PA, Wilkinson ST. Chapter Four Clinical overview of NMDA-R antagonists and clinical practice. Advances In Pharmacology 2020, 89: 103-129. PMID: 32616204, DOI: 10.1016/bs.apha.2020.04.004.ChaptersConceptsNMDA receptor antagonistReceptor antagonistGlutamatergic systemClinical trialsPathophysiology of depressionLevels of monoaminesNMDA-R antagonistsTreatment of depressionRole of glutamatePatient's therapeutic responseRecent FDA approvalIntranasal esketamineMonoamine hypothesisPathophysiological mechanismsClinical overviewTherapeutic responseCurrent treatmentClinical practiceTranslational studiesMental illnessFDA approvalNeural circuitsAntagonistDepressionPotential mechanisms